Pfizer Inc. (PFE) News
Filter PFE News Items
PFE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PFE News Highlights
- For PFE, its 30 day story count is now at 30.
- Over the past 27 days, the trend for PFE's stories per day has been choppy and unclear. It has oscillated between 1 and 9.
- EM, LI and AMP are the most mentioned tickers in articles about PFE.
Latest PFE News From Around the Web
Below are the latest news stories about PFIZER INC that investors may wish to consider to help them evaluate PFE as an investment opportunity.
The prostate cancer therapy market will soar. Here are the companies that could benefit.With the number of new prostate cancer cases rising in the US since 2014 according to the CDC, the market for therapies to treat the cancer is increasing. And the number of cases around the world is growing as well. The worldwide prostate cancer therapeutics market was estimated at $15.2B in 2021 and is expected to increase to $24.9B by 2030, according to Nova One Advisor. The consulting firm added the market is expected to grow at a CAGR of 9.4% between 2022 and 2030. With this strong growth ahead, here are the pharma and biotech companies best positioned to benefit from this trend. Novartis In... |
Little Excitement Around Pfizer Inc.'s (NYSE:PFE) EarningsWith a price-to-earnings (or "P/E") ratio of 8.4x Pfizer Inc. ( NYSE:PFE ) may be sending bullish signals at the... |
UPDATE 1-Pfizer CEO tests positive for COVID for a second timePfizer Inc Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19. "I’m feeling well and symptom free," Bourla said in a statement. Bourla, 60, back in August had contacted COVID and had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid. |
Pfizer CEO tests positive for COVID for a second time"I’m feeling well and symptom free," Bourla said in a statement. Bourla, 60, back in August had contacted COVID and had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid. Paxlovid is an antiviral medication that is used to treat high-risk people, such as older patients. |
Covid-19 Vaccine Rollout Carries Lessons for Pharma Supply Chains, Says Pfizer ExecutiveA supply-chain leader at the drugmaker says companies will map out manufacturing and distribution in advance to get lifesaving products to the public. |
Moderna seeks FDA nod for Omicron-targeted COVID shot for adolescents, younger kidsModerna Inc said on Friday it has requested U.S. authorization for use of its Omicron-targeting COVID vaccine in adolescents and children. The application for the bivalent vaccine for children between the ages of six months and under six years is expected to be completed later this year, the company said in a tweet. Earlier this week, the U.S. Centers for Disease Control and Prevention said it expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October. |
Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical HoldPfizer Inc (NASDAQ: PFE) and its partner Sangamo Therapeutics Inc (NASDAQ: SGMO) have reopened enrollment in phase 3 AFFINE study hemophilia A gene therapy trial. Trial sites will begin to resume enrollment this month, with dosing expected to restart in October. The study will evaluate the efficacy and safety of a single infusion of giroctocogene fitelparvovec in more than 60 adult male participants with moderately severe to severe hemophilia A. The primary endpoint is the impact on annualized b |
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSKThe exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024. |
Why Novavax (NVAX) Stock Was Down 13% on ThursdayNovavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100. |
Moderna Covid-19 Booster Shortage Leads to Fewer Appointments at PharmaciesA manufacturing-quality problem has led to some vaccine providers only offering the Pfizer-BioNTech booster shot. |